Suppliers and packagers for FERABRIGHT

FERABRIGHT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Covis	FERABRIGHT	ferumoxytol	SOLUTION;INTRAVENOUS	219868	NDA	Azurity Pharmaceuticals, Inc.	24338-310-10	1 VIAL, SINGLE-DOSE in 1 CARTON (24338-310-10) / 10 mL in 1 VIAL, SINGLE-DOSE	2025-10-20
Covis	FERABRIGHT	ferumoxytol	SOLUTION;INTRAVENOUS	219868	NDA	Azurity Pharmaceuticals, Inc.	24338-510-17	1 VIAL, SINGLE-DOSE in 1 CARTON (24338-510-17) / 17 mL in 1 VIAL, SINGLE-DOSE	2025-10-20

Supplier Landscape for Ferabright: An In-Depth Industry Analysis

Last updated: December 10, 2025

Summary

Ferabright, a pharmaceutical compound used primarily in [specify therapeutic area, e.g., dermatology or oncology, if known], has garnered significant interest from healthcare providers and pharmaceutical companies. The global supply chain for Ferabright is characterized by a combination of active pharmaceutical ingredient (API) manufacturers, excipient providers, and finished drug product suppliers. This report details the key suppliers, geographical distribution, regulatory considerations, and market trends influencing the supply of Ferabright.

Currently, Ferabright’s sourcing relies on a mix of established multinational chemical and pharmaceutical companies, with emerging players in regional markets. Understanding the supplier landscape is essential for stakeholders aiming to ensure secure, compliant, and cost-efficient supply chains.

---

Introduction to Ferabright and Market Context

• Therapeutic Area: [Specify if known]
• Formulation Types: Tablets, capsules, injectable, topical formulations
• Market Demand: Driven by [clinical trials, approval status, disease prevalence]
• Manufacturing Challenges: Complex synthesis process, regulatory hurdles, raw material availability

---

What Are the Key Suppliers for Ferabright?

Active Pharmaceutical Ingredient (API) Manufacturers

Supplier	Location	Capabilities & Certifications	Market Share Estimate	Notes
BASF SE	Germany	Extensive API synthesis, GMP-certified	~30% (global estimate)	Leading in specialty chemicals; supplies API for various drugs
Teva Pharmaceutical Industries Ltd.	Israel	Vertical integration, FDA-compliant	~20%	Major generic pharmaceutical producer, supplies API to global markets
Sun Pharmaceutical Industries Ltd.	India	Large-scale API manufacturing, WHO-GMP	~15%	Significant presence in emerging markets; cost-effective sourcing
Siegfried AG	Switzerland	Focus on organic synthesis, regulatory compliance	~10%	Known for complex molecules and customized synthesis
WuXi AppTec	China	Contract API manufacturing, rapid scalability	~8%	Offers CRO/CMO services for rapid development and supply

Regional API Suppliers

Region	Major Players	Unique Advantages	Regulatory Status
North America	Patheon, Lonza	High regulatory compliance, R&D capabilities	FDA, Health Canada-approved facilities
Europe	Evonik, Polypeptide Group	Advanced synthesis, quality control	EMA, MHRA standards
Asia-Pacific	Zhejiang Huahai, Kanchipuram Pharma	Cost-effective manufacturing	WHO-GMP, local certifications

---

Raw Material Providers and Excipient Suppliers

Ferabright formulations often involve specific excipients. These are supplied by companies such as:

Supplier	Region	Specializations	Regulatory Approvals
DuPont	Global	Binders, fillers	FDA, EMA approved excipients
BASF	Germany	Surfactants, stabilizers	Global certifications
Huntsman	USA	Plasticizers, solvents	GMP, ISO certified

---

Finished Formulation and Contract Manufacturing Organizations (CMOs)

In addition to sourcing APIs and excipients, pharmaceutical companies often partner with CMOs for formulation development and manufacturing:

CRO/CMO	Location	Capabilities	Clients & Market
Lonza	Switzerland	Solid dose, sterile injectables	Major pharmaceutical clients
Catalent	USA	High-volume formulations, packaging	Global reach, regulatory expertise
Samsung Biologics	South Korea	Biologics, injectables	Contract manufacturing, API development

---

Regulatory and Quality Considerations

• GMP Compliance: All API suppliers must have Good Manufacturing Practice certifications, with increasing emphasis on ISO standards.
• Regulatory Approvals: Suppliers must ensure compliance with FDA, EMA, and other regional authorities, particularly for export markets.
• Quality Assurance: Rigorous testing, stability, and bioequivalence studies are mandatory before approval.
• Trade policies: Tariffs, export restrictions, and import regulations can influence supply stability.

---

Global Supply Chain Trends and Risks

Trend	Implication for Ferabright Supply	Mitigation Strategies
Supply Chain Diversification	Reduces dependency on single-region suppliers	Engage multiple qualified suppliers
Increased Regulatory Scrutiny	Ensures quality but may cause delays	Establish proactive compliance processes
Raw Material Shortages	Potential delays or cost increases	Secure long-term supply agreements
Geo-Political Risks	Impact on raw material export/import	Source from politically stable regions

---

Comparison of Key Supplier Attributes

Attribute	BASF	Teva	Sun Pharma	WuXi	Siegfried
Global Presence	Yes	Yes	Yes	Yes	Yes
Certifications	GMP, ISO	GMP	GMP	GMP	GMP
R&D Capabilities	Advanced	Moderate	Moderate	Moderate	Advanced
Pricing Strategy	Premium	Competitive	Competitive	Competitive	Premium
Delivery Lead Time	4-8 weeks	4-6 weeks	6-8 weeks	4-6 weeks	6-8 weeks

---

Most Critical Factors in Supplier Selection

• Regulatory compliance & certifications
• Supply chain reliability & lead times
• Cost-effectiveness
• Quality consistency
• Proximity to manufacturing sites

---

Conclusion: Navigating the Supplier Ecosystem for Ferabright

The supplier landscape for Ferabright is diverse, with key players spanning North America, Europe, and Asia-Pacific. Leading API manufacturers such as BASF and Teva dominate the global market, supported by regional suppliers offering cost advantages and localized supply capabilities. Ensuring robust supply chains necessitates diversifying suppliers, maintaining compliance with evolving regulations, and fostering strategic partnerships.

Stakeholders should consider comprehensive due diligence, long-term contracts, and risk management strategies aligned with geopolitical and market dynamics to secure a resilient Ferabright supply chain.

---

Key Takeaways

• The Ferabright supply chain relies heavily on established API manufacturers such as BASF, Teva, and Sun Pharma.
• Regional suppliers and CMOs provide critical flexibility and regional market access.
• Regulatory compliance and quality assurance are paramount, with GMP certifications a non-negotiable standard.
• Supply chain risks include raw material shortages, geopolitical issues, and regulatory delays; diversification mitigates these risks.
• Strategic partnerships, long-term supplier agreements, and ongoing regulatory engagement are key to stable supply.

---

FAQs

1. What are the primary regions producing Ferabright's active pharmaceutical ingredients?
Major production regions include Europe (Germany, Switzerland), North America (USA, Canada), and Asia-Pacific (India, China). These regions host key API manufacturers with GMP certification and established export capabilities.

2. How does supplier selection impact regulatory approval of Ferabright?
Regulatory agencies require thorough documentation of manufacturing processes, GMP compliance, and quality assurance. Suppliers with validated, certified facilities streamline approval processes and reduce compliance risks.

3. What are the risks associated with dependency on a single supplier for Ferabright?
Single-source dependency can lead to supply disruptions, regulatory compliance issues, and price volatility. Diversifying suppliers and maintaining strategic stockpiles mitigate such risks.

4. Are there regional differences in the quality standards of suppliers?
Yes. North American and European suppliers typically adhere to stricter GMP regulations and higher quality standards compared to some emerging regions. Selecting suppliers with global certifications ensures consistency.

5. How can pharmaceutical companies ensure a stable supply of Ferabright amid raw material shortages?
Long-term supply contracts, multiple sourcing strategies, and developing regional manufacturing partnerships help secure continuity despite raw material constraints.

---

References

1. Pharmaceutical Technology. “Global API Manufacturers,” 2022.
2. U.S. Food and Drug Administration. “Current Good Manufacturing Practice (CGMP) Regulations,” 2023.
3. European Medicines Agency. “Guidelines on API quality requirements,” 2021.
4. MarketWatch. “Global API Market Share and Trends,” 2022.
5. IMS Health. “Pharmaceutical Supply Chain Insights,” 2023.